European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co. Ltd.'s $62 billion bid to acquire Shire plc, a deal that will likely create the largest life sciences employer in Massachusetts. The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.